6/23/2017 by Editor
Share Your Story
Paul Melmeyer with the National Organization for Rare Disorders explains the provisions of the Orphan Drug Act, how it creates incentives for the development of new treatments and why patients living with rare diseases continue to support the law.
Spread the Word:
Rare conditions are often misdiagnosed as other health...
Rare Diseases and Orphan Drugs: A Life-Saving Partnership...
700 12th St. NW, Suite 700 Washington, DC 20005 202-750-1186 | email@example.com